The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales
作者： P. Tappenden , R. Jones , S. Paisley , C. Carroll
DOI: 10.1016/J.EJCA.2007.08.017
关键词:
摘要: … in relation to clinical benefits, bevacizumab … cancer. This study was commissioned by the NHS HTA Programme to inform the National Institute for Health and Clinical Excellence’s (NICE…
elsevier.com
sci-hub.se 参考文章(19)
ArthurW. Hill, PHARMACEUTICAL SOCIETY OF GREAT BRITAIN. The Lancet. ,vol. 216, pp. 763- 764 ,(1930) , 10.1016/S0140-6736(00)86391-6
Scott D. Ramsey, M. Robyn Andersen, Ruth Etzioni, Carol Moinpour, Sue Peacock, Arnold Potosky, Nicole Urban, Quality of life in survivors of colorectal carcinoma Cancer. ,vol. 88, pp. 1294- 1303 ,(2000) , 10.1002/(SICI)1097-0142(20000315)88:6<1294::AID-CNCR4>3.0.CO;2-M
C Schmitt, G Blijham, B Jolain, P Rougier, E Van Cutsem, Medical care consumption in a phase Iii trial comparing irinotecan with infusional 5-fluorouracil (5-fu) in patients with metastatic colorectal cancer after 5-fu failure Anti-Cancer Drugs. ,vol. 10, pp. 617- 623 ,(1999) , 10.1097/00001813-199907000-00014
Fairooz Kabbinavar, Herbert I. Hurwitz, Louis Fehrenbacher, Neal J. Meropol, William F. Novotny, Grazyna Lieberman, Susan Griffing, Emily Bergsland, Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 21, pp. 60- 65 ,(2003) , 10.1200/JCO.2003.10.066
E Remák, L Brazil, Cost of managing women presenting with stage IV breast cancer in the United Kingdom. British Journal of Cancer. ,vol. 91, pp. 77- 83 ,(2004) , 10.1038/SJ.BJC.6601890
T.J. Iveson, T. Hickish, C. Schmitt, E. Van Cutsem, Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. European Journal of Cancer. ,vol. 35, pp. 1796- 1804 ,(1999) , 10.1016/S0959-8049(99)00186-0
P Tappenden, R Jones, S Paisley, C Carroll, Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer Health Technology Assessment. ,vol. 11, pp. 1- ,(2007) , 10.3310/HTA11120
A Boland, A Haycox, A Bagust, L Fitzsimmons, A randomised controlled trial to evaluate the clinical and cost-effectiveness of Hickman line insertions in adult cancer patients by nurses. Health Technology Assessment. ,vol. 7, ,(2003) , 10.3310/HTA7360
Christophe Tournigand, Thierry André, Emmanuel Achille, Gérard Lledo, Michel Flesh, Dominique Mery-Mignard, Emmanuel Quinaux, Corinne Couteau, Marc Buyse, Gérard Ganem, Bruno Landi, Philippe Colin, Christophe Louvet, Aimery de Gramont, FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study Journal of Clinical Oncology. ,vol. 22, pp. 229- 237 ,(2004) , 10.1200/JCO.2004.05.113
D Hind, P Tappenden, I Tumur, S Eggington, P Sutcliffe, A Ryan, The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation Health Technology Assessment. ,vol. 12, ,(2008) , 10.3310/HTA12150